NASDAQ : NVCT
Nuvectis Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.57 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 605.04M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 602.11M |
| Enterprise Value | 579.95M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 32.58M |
| Shares Outstanding | 32.58M |
| Shares Change (YoY) | +21.66% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 34.92% |
| Owned by Institutions (%) | 33.89% |
| Float | 21.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 54.32 |
| P/TBV Ratio | 66.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.68 |
| Quick Ratio | 1.67 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -214.58% |
| Return on Assets (ROA) | -73.07% |
| Return on Invested Capital (ROIC) | -139.03% |
| Return on Capital Employed (ROCE) | -317.86% |
| Weighted Average Cost of Capital (WACC) | 2.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.89M |
| Employee Count | 16 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +172.97% |
| 50-Day Moving Average | 21.45 |
| 200-Day Moving Average | 14.61 |
| Relative Strength Index (RSI) | 41.31 |
| Average Volume (20 Days) | 170,425 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.40M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 7.37% |
| Short % of Float | 11.32% |
| Short Ratio (days to cover) | 11.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.87M |
| Pretax Income | -27.85M |
| Net Income | -30.28M |
| EBITDA | n/a |
| EBIT | -28.87M |
| Earnings Per Share (EPS) | -$1.30 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 22.16M |
| Total Debt | n/a |
| Net Cash | 22.16M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 9.08M |
| Book Value Per Share | 0.34 |
| Working Capital | 9.08M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.51M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -19.51M |
| FCF Per Share | -$0.60 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.66% |
| Shareholder Yield | -21.66% |
| Earnings Yield | -7.06% |
| FCF Yield | -3.24% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.40 |
| Price Target Difference | 91.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |